Heart Failure Society of America Annual Meeting

Marat Fudim, MD, discusses his analysis of a US cohort from the POSEIDON study, which found a potential association between CVI and HF severity.

John Cleland, MD, PhD, discusses the results of the HF-TRACK study and the potential for the Heartfelt device to improve HF outcomes among monitored patients.

Rami Kahwash discusses his presentation at HFSA 2026, which highlighted the real-world efficacy of cardiac contractility modulation therapy.

Catch up on any data and key clinician perspectives presented at the Heart Failure Society of America Annual Scientific Meeting 2026.

Mathew Maurer, MD, discusses the results of the phase 3 REVEAL study, which highlighted this novel scanning technology’s capacity for identifying amyloidosis early.

Quin Denfeld, PhD, discusses her findings from the BIOMES-HF study, indicating worsening symptoms in patients with HF over time.

James Januzzi, MD, discusses the recently released guideline update and how it should change clinicians’ priorities in addressing and preempting HFpEF.

James Januzzi, MD, discusses his post-hoc analysis of the ATTRibute-CM study, revealing a potential predictive ratio between these 2 measurements.

Martin Maron, MD, discusses the results of his responder analysis of the trial, presented at HFSA 2026, and the implications for aficamten’s path towards approval.

These data from CARDIO-TTRansform were presented at HFSA 2026, highlighting positive data from the trial despite its failure to improve cardiovascular mortality.

James Udelson, MD, discusses the Cycle-2-PEF trial, which ultimately supports the inverse dose-response hypothesis from companion trial Cycle-1-REF.

James Udelson, MD, discusses the results of the Cycle-1-REF study, presented at HFSA 2026, that could support an inverse dose-response relationship with this PDE9 inhibitor.

Tochi Okwueze, DNP, discusses a pair of presentations at HFSA 2026 that confirm the efficacy of subcutaneous furosemide treatment for patients with HF.

Mustafa Ahmed, MD, discusses early results from the Gator SCALES-WHF trial, investigating furosemide as an alternative to in-hospital IV diuresis.

A recent retrospective analysis presented at HFSA 2026 has demonstrated the association between GLP-1 agonists, weight reduction, and PA pressures.

A new analysis of the SEQUOIA-HCM trial, presented at HFSA 2026, demonstrates aficamten’s association with improvements to an understudied aspect of the condition.

Ulrich Jorde, MD, discusses the Doraya device’s positive results in the DORAYA-HF feasibility study and Revamp Medical’s plans for a pivotal trial in early 2027.

A recent network meta-analysis presented at HFSA 2026 displays finerenone’s favorable safety profile and comparatively greater reduction of acute kidney injury risk.

A new analysis of the phase 3 ATTRibute-CM study, presented at HFSA 2026, may indicate a connection between the number of hospitalizations and mortality risk.

Get a head start on one of the biggest heart failure conferences of the year with our HFSA 2026 preview.

Ezekowitz spotlights improvement in cardiovascular mortality and heart failure hospitalization despite a failure to achieve the primary endpoint of VICTOR.

Witteles highlights the uniform improvement after the tafamidis and vutrisiran arms were both moved to the same vutrisiran dose.

An exploratory analysis of the ATTRibute-CM trial spotlighted acoramidis’s superior efficacy in lowering CVD-related risks versus placebo.

Desai details recent advancements in medicine and invasive treatments while reminding clinicians of what can still be done to protect patients.

Cedars discusses the difficulties in diagnosing heart failure in this population and how clinicians can provide their patients with better care.

A prespecified secondary analysis revealed no difference in male and female patients’ responses to tirzepatide in obesity-related HFpEF.

This set of interviews collects perspectives from 11 leading clinicians in the heart failure field, cataloguing the biggest news from 2025.

Le discusses methods by which clinicians can ease the financial burden of obtaining and adhering to medication for their patients.

The investigative therapy from Windtree Therapeutics also maintained a favorable safety and tolerability profile versus placebo.

Explore the evolving landscape of heart failure endpoints, focusing on the significance of oral diuretic intensification in outpatient care.